Skip to main content

Table 3 The pooled results and evidence quality in safety outcomes

From: Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

Outcome RCT NRCT Cohort study
Estimate (95% CI) Evidence quality a Estimate (95% CI) Evidence quality a Estimate (95% CI) Evidence quality a
Myelosuppression RR 0.55 (0.32–0.96) * Moderate RR 0.38 (0.20–0.72) * Low RR 1.11 (0.59–2.10) Very low
 Grade 3/4 myelosuppression RR 0.70 (0.29–1.66) Low RR 0.20 (0.01–3.92) Very low RR 1.25 (0.30–5.15) Very low
 Leukopenia RR 0.44 (0.18–1.11) Very low RR 1.12 (0.79–1.58) Very low
 Grade 3/4 leukopenia RR 0.80 (0.33–1.93) Very low
 Neutropenia RR 0.55 (0.28–1.06) Very low RR 1.04 (0.89–1.22) Very low
 Grade 3/4 neutropenia RR 0.96 (0.64–1.43) Very low
 Anemia RR 0.43 (0.14–1.33) Very low RR 1.05 (0.92–1.20) Very low
 Grade 3/4 anemia RR 0.95 (0.46–1.97) Very low
 Thrombocytopenia RR 1.15 (0.74–1.79) Very low
 Grade 3/4 thrombocytopenia RR 1.30 (0.49–3.47) Very low
 Hemorrhage
 Grade 3/4 hemorrhage
 Laryngeal hemorrhage RR 0.27 (0.09–0.84) * Very Low
Cardiovascular toxicity RR 0.21 (0.06–0.78) * Moderate RR 0.15 (0.02–1.20) Very low
 Cardiotoxicity RR 0.26 (0.06–1.13) Very low
Gastrointestinal Reaction RR 0.83 (0.30–2.29) Very low RR 1.25 (0.30–5.15) Very low
 Grade 3/4 gastrointestinal response RR 0.67 (0.12–3.57) Very low
 Nausea & vomiting RR 0.88 (0.51–1.51) Low RR 0.58 (0.25–1.36) Very low RR 0.97 (0.72–1.31) Very low
 Grade 3/4 nausea & vomiting RR 1.00 (0.38–2.60) Low RR 1.00 (0.16–6.14) Very low RR 1.25 (0.35–4.42) Very low
 Nausea   RR 1.17 (0.32–4.28) Very low
 Vomiting   RR 1.23 (0.63–2.40) Very low
 Diarrhea RR 1.43 (0.60–3.40) Low RR 0.60 (0.18–1.96) Very low
 Constipation   RR 0.90 (0.53–1.54) Very low
Alopecia RR 0.95 (0.82–1.09) Moderate RR 0.65 (0.42–1.00) * Very low RR 0.78 (0.31–1.95) Very low
Neurotoxicity RR 0.80 (0.23–2.77) Low
 Peripheral neurotoxicity   RR 0.58 (0.14–2.33) Very low
Liver dysfunction RR 0.71 (0.39–1.29) Low RR 0.63 (0.20–2.01) Very low
 Grade 3/4 liver dysfunction RR 0.60 (0.15–2.35) Low  
 Transaminase elevation   RR 1.48 (0.84–2.62) Very low
Fatigue RR 1.14 (0.87–1.50) Moderate RR 0.90 (0.64–1.27) Very low
 Grade 3/4fatigue RR 1.17 (0.43–3.18) Low
Muscle & joint soreness RR 0.71 (0.30–1.71) Low
Rash RR 0.61 (0.10–3.73) Very low
 Papule and purulent herpes RR 1.60 (0.49–5.25) Very low
Fever RR 0.95 (0.48–1.88) Very low
Thromboembolism RR 0.48 (0.07–3.19) Very low
Hyponatremia RR 1.28 (0.71–2.29) Very low
 Grade 3/4 hyponatremia RR 0.48 (0.10–2.19) Very low
Pain RR 1.00 (0.37–2.67) Very low
  1. a The evidence quality was evaluated by GRADE. Moderate: we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); Low: our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect); Very low: we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect)
  2. * A statistically significant difference exists (P < 0.05)